Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
相关临床试验
2
2 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
2
100.0%
- Biogen has extended its felzartamab program with an open-label long-term extension study in kidney transplant patients who developed antibody-mediated rejection or microvascular inflammation in the TRANSCEND or TRANSPIRE trials. - Felzartamab is administered as a slow intravenous infusion every eight weeks and is designed to calm immune attacks on transplanted kidneys, with safety as the study's primary goal. - Biogen executives describe antibody-mediated rejection as the foundational opportunity for felzartamab, noting there are no approved therapies and roughly 11,000 U.S. patients experience secondary kidney transplant rejection. - The company also plans to evaluate felzartamab in IgA nephropathy and membranous nephropathy, supported by nephrology infrastructure gained through its Apellis acquisition.
- Biogen reported Q2 2026 adjusted earnings of $3.60 per share on revenue of $2.74 billion, surpassing analyst estimates of $2.95 and $2.46 billion respectively. - The company raised its full-year 2026 revenue guidance to mid-single-digit growth from a prior forecast of mid-single-digit decline, citing rare disease portfolio strength. - Global sales of Alzheimer's drug Leqembi rose 15% year-over-year to approximately $184 million, with a new subcutaneous formulation expected to boost uptake. - Biogen cut its 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25, reflecting a $3.85 per share impact from the $5.6 billion Apellis Pharmaceuticals acquisition.
- At ASRS 2026 in Montreal, durable treatment strategies for wet AMD dominated research, with gene therapy, intravitreal implant and optogenetic data presented across four days. - Ocular Therapeutix reported phase 3 SOL-1 results showing a single AXPAXLI injection maintained BCVA in 74.1% of patients at Week 36 versus 55.8% with monthly aflibercept. - Nanoscope Therapeutics presented 3-year REMAIN data showing durable BCVA gains of about 3 ETDRS lines with MCO-010 in retinitis pigmentosa, alongside a rolling BLA submission. - Belite Bio's phase 3 DRAGON trial of oral tinlarebant met its primary endpoint with a 36% reduction in retinal lesion growth versus placebo in Stargardt disease.
- Inflammasome Therapeutics' dual inflammasome inhibitor K8 reduced geographic atrophy lesion growth by 54% versus control over six months in a Phase 2 trial (p=0.016). - A prespecified extrafoveal analysis showed a 4.0-letter mean BCVA advantage for K8-treated eyes versus controls (p=0.004), a functional endpoint neither approved GA therapy has met. - K8 is delivered as a bioerodible sustained-release intravitreal implant dosed once every three months, potentially reducing treatment burden compared to monthly approved therapies. - No drug-related serious adverse events, endophthalmitis, intraocular inflammation, or neovascular AMD were reported through six months in the 30-patient, 60-eye multicenter trial.
- The Dry Age-Related Macular Degeneration market across the 7MM is projected to grow at a 19.2% CAGR through 2036, driven by novel therapies and rising disease prevalence exceeding 72 million AMD cases in 2025. - Emerging oral therapies like Tinlarebant and Gildeuretinol acetate target vitamin A–driven retinal toxicity, offering alternatives to chronic intravitreal injections required by approved complement inhibitors IZERVAY and SYFOVRE. - Ocugen reported a statistically significant 31% reduction in GA lesion growth in its Phase II ArMaDa trial for gene therapy OCU410, with Phase III initiation planned for Q3 2026. - Gene therapies and regenerative medicine candidates, including Eyestem's recently approved Phase II cell therapy Eyecyte-RPE, are attracting substantial industry interest for their potential one-time administration benefit.
- Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, representing approximately $5.6 billion in upfront equity consideration, with additional contingent payments up to $4 per share based on SYFOVRE sales milestones. - The acquisition brings two FDA-approved complement-targeting therapies to Biogen's portfolio: EMPAVELI for rare kidney diseases and paroxysmal nocturnal hemoglobinuria, and SYFOVRE for geographic atrophy secondary to age-related macular degeneration. - Combined 2025 net product revenue for both drugs reached $689 million, with expected growth rates in the mid-to-high teens through at least 2028, strengthening Biogen's expansion into nephrology and immunology markets. - The transaction is expected to be increasingly accretive to Biogen's non-GAAP earnings per share starting in 2027 and meaningfully increase the company's earnings growth rate through the end of the decade.
- NovelMed Therapeutics reported positive Phase II results for Ruxoprubart in treatment-naïve PNH patients, achieving 100% transfusion independence and hemoglobin improvements of 1.5-2.7 g/dL during weekly dosing. - The company received regulatory clearance to initiate Phase II trials for subcutaneous administration, enabling weekly self-injection at home and reducing patient burden from IV infusions. - Ruxoprubart's precision targeting of activated Bb fragment provides selective alternative pathway inhibition while preserving classical pathway function for infection protection. - The drug holds FDA Orphan Drug Designation and demonstrated excellent safety with no drug-related adverse events, positioning it as a potential first-in-class monotherapy for PNH.
- Novartis announced encouraging results from the Phase III APPEAR-C3G trial showing Fabhalta (iptacopan) provided sustained improvements for patients with C3 glomerulopathy over 12 months when used alongside supportive care. - C3 glomerulopathy is a serious kidney disorder that frequently progresses to kidney failure within a decade of diagnosis, representing a significant unmet medical need. - The APPEAR-C3G study represents the first Phase III trial for an oral Factor B inhibitor targeting the alternative complement pathway in this rare disease. - The complement 3 glomerulopathy pipeline includes 3+ key companies developing therapies, with emerging treatments like NM8074, Pegcetacoplan, and LNP023 expected to impact the market significantly.
- The FDA approved multiple breakthrough therapies in 2025, including semaglutide for chronic kidney disease, atrasentan for IgA nephropathy, and pegcetacoplan for C3 glomerulopathy, marking a shift toward precision-driven nephrology care. - IgA nephropathy emerged as a major therapeutic focus with accelerated approval of atrasentan and positive phase 3 results for telitacicept and sibeprenlimab, demonstrating the transition from supportive care to targeted, disease-modifying strategies. - The CONFIDENCE trial showed that simultaneous initiation of finerenone and SGLT2 inhibitors was safe and effective in chronic kidney disease with type 2 diabetes, supporting proactive combination therapy over stepwise treatment escalation. - The FDA cleared the first xenotransplant trial for gene-edited kidneys, representing a translational step toward addressing organ shortages for patients with end-stage kidney disease.
- The dry age-related macular degeneration market is expected to experience substantial growth through 2034, driven by the uptake of recently approved therapies and the anticipated launch of emerging treatments. - Multiple innovative therapies are advancing through clinical trials, including Gildeuretinol from Alkeus Pharmaceuticals, which demonstrated a 0.25 sq mm per year reduction in geographic atrophy lesion growth compared to placebo in its Phase II/III SAGA trial. - The United States represents the largest market opportunity with approximately 21 million prevalent cases in 2024, while dry AMD accounts for nearly 90% of all AMD cases, representing a vast untapped therapeutic opportunity.
